Last week, the Department of Defense published the 2012 edition of the Manual for Courts-Martial (MCM).
The Manual contains the Rules for Courts-Martial (RCM), the Military Rules of Evidence (MRE), and the Uniform Code of Military Justice. The latest edition incorporates legislative amendments and other changes introduced since the previous edition was published in 2008.
The Manual details the elements of various crimes such as “Aiding the Enemy” (Article 104), which is among the charges pending against Bradley Manning, who is suspected of having provided classified and other restricted records to WikiLeaks without authorization.
“No unauthorized communication, correspondence, or intercourse with the enemy is permissible,” according to the Manual’s explanation of Article 104 (which has not been amended recently).
“The intent, content, and method of the communication, correspondence, or intercourse are immaterial. No response or receipt by the enemy is required. The offense is complete the moment the communication, correspondence, or intercourse issues from the accused. The communication, correspondence, or intercourse may be conveyed directly or indirectly.”
“Giving intelligence to the enemy is a particular case of corresponding with the enemy made more serious by the fact that the communication contains intelligence that may be useful to the enemy for any of the many reasons that make information valuable to belligerents. This intelligence may be conveyed by direct or indirect means.”
See, more generally, Military Justice: Courts-Martial, An Overview from the Congressional Research Service, March 14, 2012.
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.